Lifesci Capital Has Positive Estimate for TARA Q1 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at Lifesci Capital increased their Q1 2026 earnings per share estimates for shares of Protara Therapeutics in a research report issued to clients and investors on Tuesday, March 10th. Lifesci Capital analyst C. Zhu now forecasts that the company will earn ($0.34) per share for the quarter, up from their prior estimate of ($0.38). The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Lifesci Capital also issued estimates for Protara Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($1.49) EPS.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

TARA has been the subject of a number of other research reports. JPMorgan Chase & Co. assumed coverage on Protara Therapeutics in a research report on Wednesday, March 4th. They set an “overweight” rating and a $27.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Tuesday, February 10th. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a report on Tuesday. Piper Sandler began coverage on shares of Protara Therapeutics in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Protara Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Protara Therapeutics Stock Performance

Shares of Protara Therapeutics stock opened at $5.26 on Friday. The business’s 50 day simple moving average is $6.10 and its 200 day simple moving average is $5.37. Protara Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.82. The firm has a market cap of $271.57 million, a PE ratio of -3.98 and a beta of 1.40.

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC grew its holdings in Protara Therapeutics by 21.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock worth $27,379,000 after purchasing an additional 910,285 shares during the period. Velan Capital Investment Management LP raised its stake in Protara Therapeutics by 32.5% in the fourth quarter. Velan Capital Investment Management LP now owns 2,834,652 shares of the company’s stock valued at $15,109,000 after buying an additional 695,652 shares during the period. Integral Health Asset Management LLC lifted its position in shares of Protara Therapeutics by 60.7% in the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock valued at $11,992,000 after buying an additional 850,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Protara Therapeutics by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock valued at $8,283,000 after buying an additional 102,176 shares during the last quarter. Finally, Acorn Capital Advisors LLC boosted its stake in shares of Protara Therapeutics by 36.9% during the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock worth $5,309,000 after acquiring an additional 472,315 shares during the period. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics News Roundup

Here are the key news stories impacting Protara Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised its 2026 outlook across the board — boosting Q1 to ($0.34) from ($0.38), Q2 to ($0.37) from ($0.41), Q3 to ($0.39) from ($0.44), Q4 to ($0.41) from ($0.46) and lifting FY2026 to ($1.49) from ($1.73). These upgrades point to modestly improved expectations for near‑term results. MarketBeat TARA
• Neutral Sentiment: HC Wainwright retained a “Buy” rating and a $23.00 price target on TARA, which supports longer‑term upside potential if Protara meets clinical/corporate milestones. That endorsement may limit downside even as estimates were trimmed. MarketBeat TARA
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and later‑year EPS forecasts (examples: Q1 to ($0.39) from ($0.33), Q2 to ($0.40) from ($0.34), Q3 to ($0.41) from ($0.35), Q4 to ($0.42) and FY2026 to ($1.61) from ($1.37); FY2027–FY2029 and FY2028 estimates were also reduced). Those downgrades signal increased expected cash burn or slower commercialization/progression assumptions and likely pressured the stock today. MarketBeat TARA

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.